- Home
- CPRX
as 08-07-2025 4:00pm EST
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 2.6B | IPO Year: | 2006 |
| Target Price: | $32.83 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.65 | EPS Growth: | 183.96 |
| 52 Week Low/High: | $16.05 - $26.58 | Next Earning Date: | 08-06-2025 |
| Revenue: | $558,499,000 | Revenue Growth: | 28.55% |
| Revenue Growth (this year): | 16.37% | Revenue Growth (next year): | 8.80% |
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sundaram Preethi | CPRX | Chief Strategy Officer | Jun 10 '25 | Sell | $26.42 | 3,924 | $103,648.84 | 41,081 | |
| MCENANY PATRICK J | CPRX | Director | Jun 6 '25 | Sell | $26.03 | 200,000 | $5,217,338.42 | 4,453,450 | |
| Daly Richard J | CPRX | President and CEO | May 30 '25 | Sell | $24.86 | 70,000 | $1,740,200.00 | 199,764 | |
| INGENITO GARY | CPRX | Chief Med. & Reg. Officer | May 13 '25 | Sell | $23.66 | 244,000 | $5,775,720.00 | 68,873 |
Latest Catalyst Pharmaceuticals Inc. News
CPRX Breaking Stock News: Dive into CPRX Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Catalyst (CPRX) Loses 12.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Argus Research
a month ago
CPRX: Lowering target price to $23.00
Zacks
2 months ago
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Zacks
2 months ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Simply Wall St.
2 months ago
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Reports Strong Q1 2025 Earnings Growth
Zacks
2 months ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 06/11/2025
Argus Research
2 months ago
CPRX: Raising target price to $28.00
Compare CPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.